3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
2
Carcinoma, Transitional Cell
2
Urologic Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
74
Capecitabine
60
Paclitaxel
59
Fluorouracil
58
Oxaliplatin
57
Bevacizumab
51
Docetaxel
50
Leucovorin
48
Nivolumab
40
Cisplatin
40
Irinotecan
39
Carboplatin
37
Cetuximab
34
pembrolizumab
32
Radiosurgery
32
Trastuzumab
30
Radiotherapy
27
Everolimus
24
Sorafenib
23
Pemetrexed
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Ipilimumab
19
Cyclophosphamide
19
Panitumumab
18
Zoledronic Acid
17
Lapatinib
17
Erlotinib Hydrochloride
17
Prednisone
16
pazopanib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasm Metastasis
×
apatorsen
×
Clear all
NCT01844817
2017-05-16
Rainier
SCRI Development Innovations, LLC
Phase 2
Completed
132 enrolled
9 charts